In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE _Ala63Pro mutation during treatment in a pre-XDR TB patient
- PMID: 34795042
- PMCID: PMC8943273
- DOI: 10.1183/13993003.02102-2021
In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE _Ala63Pro mutation during treatment in a pre-XDR TB patient
Abstract
This letter describes microevolution of a pre-XDR MTB strain isolated from a pulmonary TB patient over an 18-month exposure to BDQ. MDR-TB therapies with BDQ require a functional background regimen to prevent emergence of additional resistance.
Conflict of interest statement
Conflict of interest: None declared.
Figures
Comment in
References
-
- World Health Organization . WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva, World Health Organization, 2019. - PubMed
-
- World Health Organization . WHO Consolidated Guidelines on Tuberculosis. Geneva, World Health Organization, 2020.
-
- World Health Organization . Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines used in the Treatment of Drug-resistant Tuberculosis. Geneva, World Health Organization, 2018.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources